Potential Drug Interaction Between ALXN2040 and Rosuvastatin

This is an open-label, 2-treatment, 2-period, fixed-sequence DDI study in healthy adult participants. This study will comprise of: * Screening duration of 27 days. * Two treatment periods: Approximately 14 days. Treatment Period 1: 6 days Treatment Period 2: 8 days * Follow-up: 7 (± 2) days following the final dose of study intervention. There will be a washout period of at least 5 days between the single dose of rosuvastatin in Treatment Period 1 and the first dose of ALXN2040 in Treatment Period 2. Each participant will be involved in the study for approximately 48 days.